• Rate this Story
  • 0
  • 0

By Gopi Chandra Kharel | February 1, 2013 3:32 AM PST

Health Canada will conduct a review of a controversial acne medication that has been often prescribed for birth control.

This comes in the wake of a media speculation that the drug could have played a major role in the deaths of 11 young women in Canada and four in France. The latter has temporarily suspended the sale of the drug.

The European Medicines Agency Thursday said that it would launch an investigation into the drug, also sometimes referred to as Dianette

The acne drug called Diane- 35 has been known for long to have adverse side effects, yet, it remains a popular resort for young girls concerned about acne or skin troubles.

According to a report by the Star, 195 cases of adverse reactions to Diane-35 have come under the preview of Health Canada since 2000. Majority of the cases were considered to have effects causing a life-threatening condition that resulted in hospitalization, disability, or death, the report says.

Health Canada since 2002 has regulated a limited use of Diane-35 and it is only advised for treating severe acne. But many health practitioners also prescribe them for birth control.

Diane-35 is packaged like other birth control pills in a 28 pill holder which has been designed to coincide with the menstrual cycle. Menstrual cycle and acne are popularly thought to be related to each other.

Many pills used for birth control are thought to help acne by stabilizing hormone levels, according to popular believe that can't be verified. An ingredient in Diane-35 called cyproterone acetate is considered to be very powerful for positive results in skin. The drug, never-the-less, is also likely to cause blood clotting which is why it is not advised to be used as an oral contraceptive.

It was during 1990s that this drug was largely advertised in the streets of Canada which saw attractive advertising billboards projecting Diane-35 to be "The Acne Solution".

To contact the editor, e-mail:

  • Rate this Story
  • 0
  • 0
This article is copyrighted by IBTimes.ca, the business news leader

Join the Conversation

Follow IBTimes

E-Newsletters

We value your privacy. Your email address will not be shared.